Skip to main
KRRO

KRRO Stock Forecast & Price Target

KRRO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Korro Bio is a promising biopharmaceutical company with a solid plan for developing and commercializing genetic medicines based on RNA editing. Their focus on targeting hyperammonemia, a well-established disease with clear metrics for approval, provides a clear path for success with their lead program KRRO-121. Their recent PIPE financing and strong balance sheet support their continued growth and we expect their stock to perform well in the near future, with our Buy rating and updated 12-month price target of $15 per share.

Bears say

Korro Bio is currently generating no revenue from its products, which is a significant financial concern. Additionally, the company has yet to bring any of its products to market and its clinical trials have been delayed, leading to further uncertainty and potential financial setbacks. The lack of revenue and potential obstacles in the company's pipeline make it a risky investment with a negative outlook on its stock.

KRRO has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Frequency Therapeutics Inc (KRRO) Forecast

Analysts have given KRRO a Buy based on their latest research and market trends.

According to 9 analysts, KRRO has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Frequency Therapeutics Inc (KRRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.